Company Encyclopedia
View More
name
ZHEJIANG ZHENYUAN
000705.SZ
Zhejiang Zhenyuan Share Co.,Ltd. engages in the manufacture and wholesale of pharmaceutical products in China and internationally. Its products include Chinese herbal medicines and slices, Chinese patent medicines, chemical raw materials, chemical preparations, antibiotics, biochemical drugs, biological products, medical devices, chemical reagents, glass instruments, etc. The company also provides pharmaceutical logistics, health services, etc.; and engages in the wholesale and retail of pharmaceutical products, pre-packaged food, and bulk food and dairy products.
402.16 B
000705.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking19/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.37%C
    • Profit Margin1.77%C
    • Gross Margin27.94%C
  • Growth ScoreE
    • Revenue YoY-30.46%E
    • Net Profit YoY-14.65%D
    • Total Assets YoY-7.23%D
    • Net Assets YoY2.20%C
  • Cash ScoreC
    • Cash Flow Margin5651.59%A
    • OCF YoY-30.46%E
  • Operating ScoreB
    • Turnover0.85B
  • Debt ScoreB
    • Gearing Ratio33.43%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ZHEJIANG ZHENYUAN terminates the issuance of stocks to specific objects and withdraws the application documents

    According to the Zhitong Finance APP, Zhejiang Zhenyuan announced that since the company disclosed the issuance of shares to specific targets, the company and relevant intermediary institutions have actively promoted various tasks. Now, considering the current capital market environment and the company's overall development plan, after fully communicating and prudently analyzing with relevant parties, the company has decided to terminate the issuance of shares to specific targets and has proactively applied to the Shenzhen Stock Exchange to withdraw the relevant application documents

    Zhitong·
    SZ
    000705
    +0.90%
    Zhitong·
    SZ
    000705
    +0.90%

    ZHEJIANG ZHENYUAN: The S1 production line is scheduled to officially start production at the end of August

    On August 27th, ZHEJIANG ZHENYUAN stated on the interactive platform that the S1 production line of Zhenyuan Biotechnology is scheduled to officially start production by the end of August 2025

    Zhitong·
    SZ
    000705
    +0.90%
    Zhitong·
    SZ
    000705
    +0.90%

    ZHEJIANG ZHENYUAN: The synthetic biology project of Zhenyuan Bio is expected to be put into production in the third quarter

    ZHEJIANG ZHENYUAN stated on the interactive platform that the synthetic biology project of Zhenyuan Biotech is expected to be put into production in the third quarter

    Zhitong·
    SZ
    000705
    +0.90%
    Zhitong·
    SZ
    000705
    +0.90%

    The synthetic biology concept strengthens, ALK hits the limit up

    The synthetic biology concept is gaining strength. As of 10:16 AM, ZHEJIANG ZHENYUAN and ALK have reached the daily limit, Boji Pharmaceutical has risen over 10%, and Biological Shares, Kexing Pharmaceutical, and Hongbo Pharmaceutical have all increased by over 5%

    Zhitong·
    SZ
    002940
    -1.44%
    SZ
    000705
    +0.90%
    Zhitong·
    SZ
    002940
    -1.44%
    SZ
    000705
    +0.90%

    Pharmaceutical stocks continued to rise in the afternoon, with LIVZON GROUP and nearly ten other stocks hitting the daily limit

    In the afternoon, the pharmaceutical stocks continued to rise, with both innovative drugs and generic drugs performing well. Stocks such as LIVZON GROUP, MEDISAN, Qianhong Pharmaceutical, Wanbangde, Asia-Pacific Pharmaceutical, and ZHEJIANG ZHENYUAN all hit the daily limit, while Guangshengtang, Laimei Pharmaceutical, and Wohu Biological rose over 10%. On the news front, the National Organization for Drug Procurement Office announced the selection of the 11th batch of centralized procurement varieties on the 15th. After three stages of screening, 55 varieties were included in the reporting scope of the 11th batch of centralized procurement. The procurement rules will generally adhere to the principles of "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition."

    Zhitong·
    SZ
    002900
    -3.79%
    SZ
    000513
    -0.08%
    HK
    01513
    +0.84%
    Zhitong·
    SZ
    002900
    -3.79%
    SZ
    000513
    -0.08%
    HK
    01513
    +0.84%
    © 2025 Longbridge｜Disclaimer